CAR

Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Therapy for Rheumatoid Arthritis at American College of Rheumatology Convergence 2023

Retrieved on: 
Monday, November 6, 2023

Sonoma Biotherapeutics, Inc. , a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will present preclinical data from its autologous chimeric antigen receptor (CAR) Treg therapy product candidate for the treatment of rheumatoid arthritis (RA) at the American College of Rheumatology (ACR) Convergence 2023, taking place in San Diego, California from November 10-15th.

Key Points: 
  • Sonoma Biotherapeutics, Inc. , a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will present preclinical data from its autologous chimeric antigen receptor (CAR) Treg therapy product candidate for the treatment of rheumatoid arthritis (RA) at the American College of Rheumatology (ACR) Convergence 2023, taking place in San Diego, California from November 10-15th.
  • “Our CAR-Treg product candidate, SBT-77-7101, is designed to target proteins that accumulate in the joints and blood of patients with RA,” said Mark D. Eisner, M.D., MPH, Chief Medical Officer of Sonoma Biotherapeutics.
  • “Results from this study show that we can detect CAR-reactive citrullinated antigens in both synovial fluid and blood.
  • In addition, these protein levels correlated with systemic markers of inflammation.

A2 Bio Presents Oral and Poster Presentations Highlighting BASECAMP-1 and EVEREST-1 Patient Screening at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Thursday, November 2, 2023

Additionally, A2 Bio is presenting two posters on November 4, 2023, detailing the BASECAMP-1 master pre-screening trial and EVEREST-1 CAR T interventional trial.

Key Points: 
  • Additionally, A2 Bio is presenting two posters on November 4, 2023, detailing the BASECAMP-1 master pre-screening trial and EVEREST-1 CAR T interventional trial.
  • “BASECAMP-1 provides patients an early opportunity to be identified and triaged to the appropriate EVEREST logic-gate Tmod™ CAR T trial.
  • A2 Bio has partnered with Tempus, a leader in precision medicine, to bring the latest technology to patient screening.
  • Details of the presentations are below:
    The two posters will be available on the A2 Bio website after November 4, 2023.

Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023

Retrieved on: 
Thursday, November 2, 2023

Additional Yescarta research will focus on new four-year follow-up results from ZUMA-5 evaluating Yescarta in R/R indolent non-Hodgkin lymphoma, including follicular lymphoma and marginal zone lymphoma.

Key Points: 
  • Additional Yescarta research will focus on new four-year follow-up results from ZUMA-5 evaluating Yescarta in R/R indolent non-Hodgkin lymphoma, including follicular lymphoma and marginal zone lymphoma.
  • Additionally, four-year overall survival data from ZUMA-2 and a ZUMA-18 primary analysis of expanded access in R/R MCL will be highlighted in an oral presentation.
  • New data from the Phase 1 study of CART-dd BCMA will be presented from our multiple myeloma partner, Arcellx.
  • CART-ddBCMA is Arcellx’s BCMA-specific CAR-modified T-cell therapy with a novel D-Domain BCMA binder that may improve CAR T-cell binding and killing of multiple myeloma cells.

Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 1, 2023

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including progress on its strategic transformation and a corresponding restructuring of operations and workforce reduction, and reported third quarter 2023 financial results.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including progress on its strategic transformation and a corresponding restructuring of operations and workforce reduction, and reported third quarter 2023 financial results.
  • As a result of this restructuring, Sangamo is reducing its US workforce by approximately 40%, or approximately 162 roles.
  • Sangamo expects to incur approximately $8 million-$10 million in one-time restructuring costs in the fourth quarter of 2023.
  • Revenues for the third quarter ended September 30, 2023 were $9.4 million, compared to $26.5 million for the same period in 2022.

T-cell Therapy Market Size to Grow USD US$ 76.6 billion from 2023-2033 | Says Transparency Market Research Inc.

Retrieved on: 
Monday, November 6, 2023

WILMINGTON, DEL., Nov. 6, 2023 /PRNewswire/ --The global T cell therapy market was estimated to have acquired US$ 5.3 billion in 2022. It is anticipated to register a 27.9% CAGR from 2023 to 2033 and by 2033, the market is likely to gain US$ 76.6 billion.Expanding the infrastructure for T cell therapy administration, such as specialized treatment centers and healthcare provider training, can enhance patient access and outcomes.

Key Points: 
  • Research and clinical trials are exploring the use of T cell therapy in various disease indications beyond cancer, including autoimmune diseases, infectious diseases, and solid tumors.
  • Global Market for T Cell Therapy: Regional Outlook
    Various reasons are propelling the growth of the T cell therapy market in different regions.
  • The regions include,
    Biotech companies, academic institutions, and pharmaceutical firms in Europe have been investing in T cell therapy research and development.
  • Breyanzi is the second CAR T cell therapy to be approved by the FDA for the treatment of LBCL.

Generate:Biomedicines and Roswell Park Comprehensive Cancer Center Enter into a Collaboration Agreement to Accelerate Novel Cell Therapies for Oncology Using Generative AI

Retrieved on: 
Wednesday, November 1, 2023

In ovarian cancer alone, an estimated 314,000 women worldwide are diagnosed and over 200,000 women die each year.

Key Points: 
  • In ovarian cancer alone, an estimated 314,000 women worldwide are diagnosed and over 200,000 women die each year.
  • View the full release here: https://www.businesswire.com/news/home/20231101307318/en/
    Under the collaboration agreement, Generate:Biomedicines and Roswell Park will contribute toward creating optimized cell therapies, where a patient’s T cells are engineered to recognize and kill tumors.
  • The collaboration combines the programmability and scalability of The Generate Platform and Roswell Park’s expertise in cell therapy design, clinical development, and manufacturing to bring best-in-class cell therapies to patients.
  • It is anticipated that Roswell Park will serve as a site and recommend lead investigators for Phase I and II clinical trials.

Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 1, 2023

“We are proud to expand our global tab-cel partnership with Pierre Fabre Laboratories, who is committed to delivering this first-of-its-kind treatment to patients in need across the globe,” said Pascal Touchon, President and Chief Executive Officer of Atara.

Key Points: 
  • “We are proud to expand our global tab-cel partnership with Pierre Fabre Laboratories, who is committed to delivering this first-of-its-kind treatment to patients in need across the globe,” said Pascal Touchon, President and Chief Executive Officer of Atara.
  • In addition, Pierre Fabre Laboratories has agreed to reimburse Atara for expected tab-cel global development costs through Biologics License Application (BLA) transfer, and purchase current and future tab-cel inventory through the BLA transfer date.
  • PJT Partners served as the exclusive financial advisor to Atara and Fenwick & West LLP served as legal counsel to Atara.
  • Concurrent with the execution of the global tab-cel partnership, Atara is undertaking a strategic restructuring and is reducing its current workforce by approximately 30 percent.

SOTIO Presents Data on SOT201 Immunocytokine and Other Programs at SITC Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023

SOTIO Biotech , a clinical-stage immuno-oncology company owned by PPF Group, today announced it will be presenting new preclinical data at the Society for Immunotherapy of Cancer’s 38th Annual Meeting taking place November 1-5, 2023 in San Diego, California.

Key Points: 
  • SOTIO Biotech , a clinical-stage immuno-oncology company owned by PPF Group, today announced it will be presenting new preclinical data at the Society for Immunotherapy of Cancer’s 38th Annual Meeting taking place November 1-5, 2023 in San Diego, California.
  • Data to be presented include new preclinical results supporting the continued development of SOT201, a next-generation PD-1-inhibiting cytokine that SOTIO is progressing toward a planned first-in-human study in the second quarter of 2024.
  • SOT201 is an antibody-cytokine fusion protein that could improve upon the efficacy of approved checkpoint inhibitors by combining PD-1 blockade with IL-15 immune stimulation in a single therapeutic construct.
  • Additional poster presentations at the meeting will include preclinical data on the synergistic effects of SOTIO’s IL-15 superagonist in combination with CAR T-cell therapies, as well as data on SOTIO’s IL-15 superagonist nanrilkefusp alfa.

Capstan Therapeutics to Present Preclinical Data at SITC Demonstrating Rapid Anti-Primary B Cell and Anti-Tumor Activity in Mice with Proprietary Targeted Lipid Nanoparticles Delivering an Anti-CD19 CAR mRNA Construct

Retrieved on: 
Tuesday, October 31, 2023

Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery utilizing targeted lipid nanoparticles (tLNP), today announced it will present preclinical data showing rapid and robust anti-tumor and anti-primary B cell activity in humanized mice by tLNP administration delivering an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR), at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, California.

Key Points: 
  • Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery utilizing targeted lipid nanoparticles (tLNP), today announced it will present preclinical data showing rapid and robust anti-tumor and anti-primary B cell activity in humanized mice by tLNP administration delivering an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR), at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, California.
  • “We have demonstrated efficient and therapeutically relevant delivery of mRNA CAR payloads to human T cells.
  • This resulted in rapid and profound pharmacodynamic effect in two mouse models, comprising eradication of human primary B cells or Nalm6 leukemic cells, respectively.
  • These data provide a springboard for developing novel, in vivo CAR therapies that may overcome access and clinical performance issues with currently available ex vivo CAR therapies, with broad applicability in autoimmune and oncology indications.”

Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer

Retrieved on: 
Tuesday, October 31, 2023

Kite, a Gilead Company (Nasdaq: GILD) and Epicrispr Biotechnologies (“Epic Bio”), today announced the companies have entered into a research collaboration and license agreement using Epic Bio’s proprietary gene regulation platform to develop next-generation cancer cell therapies.

Key Points: 
  • Kite, a Gilead Company (Nasdaq: GILD) and Epicrispr Biotechnologies (“Epic Bio”), today announced the companies have entered into a research collaboration and license agreement using Epic Bio’s proprietary gene regulation platform to develop next-generation cancer cell therapies.
  • “Cell-based cancer immunotherapies have reshaped modern cancer care, but we have still only scratched the surface of their potential benefit for patients.
  • Kite will make an upfront payment to Epic Bio and Epic Bio will be eligible to receive performance-based development, regulatory and sales milestone payments.
  • Epic Bio is also eligible to receive tiered royalties on any approved products that result from the collaboration.